Gerard J. Criner
Temple University
675 Papers
2K Citations
Gerard J. Criner is an academic researcher from Temple University. The author has contributed to research in topics: Medicine & COPD. The author has an hindex of 73, co-authored 541 publications. Previous affiliations of Gerard J. Criner include University of North Carolina at Chapel Hill & Queen Elizabeth Hospital Birmingham.
Chat about Author
Papers
Role of Imaging in Bronchoscopic Lung Volume Reduction Using Endobronchial Valve: State of the Art Review.
Chandra Dass,Alyssa R. Goldbach,Farouk Dako,Maruti Kumaran,Robert M. Steiner,Gerard J. Criner +5 more
TL;DR: On the basis of the results of multiple randomized clinical trials, the recommendations of the original 2016 Expert Panel Report on BLVR usage criteria of EBVs have been updated in 2019 and the outcome of EBV therapy is maximized in certain image-based COPD phenotypes.
11
Current precautions and future directions in lung transplantation during the COVID-19 pandemic - a single center cohort study.
TL;DR: In insights as specialists at a high‐volume center located in a geographical area with high infection rates, there is an urgent need for evidence‐based directions to move forward in solid organ transplantation.
11
Hiatal Hernia on Chest High-Resolution Computed Tomography and Exacerbation Rates in COPD Individuals.
TL;DR: The presence of HHs on inspiratory HRCT scan did not predict worse symptoms or exacerbation rate in COPD individuals, and those with HHs were older, more obese, and predominantly female compared to those without HHs.
Sonographic Evaluation of Diaphragmatic Dysfunction: Technique, Interpretation, and Clinical Applications
Chandra Dass,Farouk Dako,Scott Simpson,Nathaniel Marchetti,Robert M. Steiner,Gerard J. Criner +5 more
TL;DR: The purpose of this review article is to provide readers with the essentials for performing diaphragm ultrasonography, image interpretation, and the technical limitations one needs to be aware of.
11
Idiopathic pulmonary fibrosis: A guide for nurse practitioners.
TL;DR: Iiopathic pulmonary fibrosis is a rare disease characterized by decline in lung function, dyspnea, and cough, and two antifibrotic drugs (nintedanib and pirfenidone) have been approved for the treatment of IPF.
10